Abstract
Few data exist on the etiology, presentation, prognosis, and management of fungal endophthalmitis (FE) in cancer patients. FE cases were identified by reviewing the ophthalmology reports and microbiology cultures of patients at The University of Texas M. D. Anderson Cancer Center. We retrospectively reviewed the medical records and obtained information related to malignancy, fungal infection and its management, visual outcome, and mortality. We compared FE caused by Candida spp. (CE) to FE caused by molds (ME). Of the 102 cancer patients with a fungal infection for whom an ophthalmology consult was requested, 23 met the criteria for definite (N = 6) or probable (N = 17) FE (8 with CE, 15 with ME). All of the patients with ME had hematologic malignancies, whereas half of the patients with CE had solid tumor (P = .008). Only patients with CE had a history of surgery within 30 days of FE diagnosis (38%, P = .03). Fungal pneumonia [17 (74%)] and disseminated infection [14, (61%)] were common. The most common presenting symptoms were decreased vision [16 (70%)] and ocular pain [14 (61%)]. All treated patients received systemic antifungals (combination therapy in 72% of the cases). Seven patients (30%) underwent vitrectomy. Only one patient received intraocular injection of amphotericin B along with systemic antifungals. Four-week mortality was high [13 (57%)], especially in ME (73%, P = .04). Among the eight surviving patients where visual acuity could be assessed, visual outcome improved or remained stable in five (63%). FE in cancer patients occurs in the setting of severe, frequently disseminated opportunistic mycoses, is caused predominantly by hyalohyphomycetes, and is a marker for high 4-week mortality.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Nucci M, Anaissie E (2006) Emerging fungi. Infect Dis Clin North Am 20:563–579
Marr KA, Carter RA, Crippa F, Wald A, Corey L (2002) Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 34:909–917
Clark TA, Hajjeh RA (2002) Recent trends in the epidemiology of invasive mycoses. Curr Opin Infect Dis 3:156–161
Kontoyiannis DP, Bodey GP (2002) Invasive aspergillosis in 2002: an update. Eur J Clin Microbiol Infect Dis 21:161–172
Klotz SA, Penn CC, Negvesky GJ, Butrus SI (2000) Fungal and parasitic infections of the eye. Clin Microbiol Rev 13:662–685
Lynn WA, Lightman S (2004) The eye in systemic infection. Lancet 364(9443):1439–1450
Smith SR, Kroll AJ, Lou PL, Ryan EA (2007) Endogenous bacterial and fungal endophthalmitis. Int Ophthalmol Clin 47:172–183
Schiedler V, Scott IU, Flynn HW, Davis JL, Benz MS, Miller D (2004) Culture proven endogenous endophthalmitis: clinical features and visual outcomes. Am J Ophthalmol 4:725–731
Binder MI, Chua J, Kaiser PK, Procop GW, Isada C (2003) Endogenous endophthalmitis: an 18-year review of culture positive cases at a tertiary cancer center. Medicine (Baltimore) 2:97–105
Feman SS, Nichols JC, Chung SM, Theobald TA (2002) Endophthalmitis in patients with disseminated fungal disease. Trans Am Ophthalmol Soc 100:67–70
Ascioglu S, Rex JH, de Pauw B et al (2003) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34:7–14
Ishibashi Y (1993) Proposed classification of stages of endogenous fungal endophthalmitis. Jpn J Ophthalmol 47:845–849
Rao NA, Hidayat A (2001) A comparative clinicopathologic study of endogenous mycotic endophthalmitis: variations in clinical and histopathologic changes in candidiasis compared to aspergillosis. Am J Ophthalmol 2:244–251
Okada AA, Johnson RP, Liles WC, D’Amico DJ, Sullivan Baker A (1994) Endogenous bacterial endophthalmitis. Ophthalmology 101:832–838
Takebayashi H, Mizota A, Tanaka M (2006) Relation between stage of endogenous endophthalmitis and prognosis. Graefes Arch Clin Exp Ophthalmol 244:816–820
Osthoff M, Hilge R, Schulze-Dobold C, Bogner JR (2006) Endogenous endophthalmitis with azole resistant Candida albicans: case report and review of the literature. Infection 34:285–288
Breit SM, Hariprasad SM, Mieler WF, Shah GK, Mills MD, Grand MG (2005) Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. Am J Ophthalmol 139:135–140
Wiederhold NP, Lewis RE (2003) The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy. Expert Opin Investig Drugs 12:1313–1333
Menezes AV, Sigesmund DA, Demajo WA, Devenyi RG (1994) Mortality of hospitalized patients with Candida endophthalmitis. Arch Intern Med 154:2093–2097
Conflict of interest statement
D.P.K. has received research support and honoraria from Merck, Fujisawa, Pfizer, and Schering Plough. R.E.L. has received research support from Merck, Fujisawa, Pfizer, and Schering Plough. I.I.R. has received research support and honoraria from Schering-Plough, Astellas Pharma Inc., Enzon Pharmaceuticals, Merck & Co., Inc., and Wyeth, Inc.
All other authors
No conflicts.
Financial support
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lamaris, G.A., Esmaeli, B., Chamilos, G. et al. Fungal endophthalmitis in a tertiary care cancer center: a review of 23 cases. Eur J Clin Microbiol Infect Dis 27, 343–347 (2008). https://doi.org/10.1007/s10096-007-0443-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10096-007-0443-9